Severe perioperative immune-related adverse events requiring intensive care in patients with gastric cancer: a case series Authors: Hiroshi Hadatsuki, Maho Takuwa, YuKi Takenaka, Yurina Fujisaki, Rei Ogawa, Takeyuki Wada, Tsutomu Hayashi, Yukinori Yamagata, Takaki Yoshikawa, Yasuyuki Seto Published: 2026 ABSTRACT BackgroundThe treatment strategy for advanced gastric cancer is significantly changing with the development of immune checkpoint inhibitors. While the efficacy of immune checkpoint inhibitors has been demonstrated, immune-related adverse events can present a wide spectrum of symptoms, ranging from mild and non-specific to severe symptoms. In some cases, intensive care unit management is required. Despite the widespread application of immune checkpoint inhibitor therapy, perioperative immune-related adverse events remain under-reported and insufficiently discussed.Case presentationCase 1 is a 46-year-old Japanese female underwent laparoscopic proximal gastrectomy after S-1, oxaliplatin plus nivolumab therapy for unresectable locally advanced esophagogastric junction cancer and developed diabetic ketoacidosis and fulminant type 1 diabetes mellitus 37 days after surgery. Case 2 is a 78-year-old Japanese male underwent staging laparoscopy after S-1, oxaliplatin plus nivolumab therapy for unresectable advanced gastric cancer and developed fulminant type 1 diabetes mellitus and bullous pemphigoid 13 days after surgery. Case 3 is a 64-year-old Japanese male underwent distal gastrectomy with D2 lymph node dissection and para-aortic lymph node sampling after S-1, oxaliplatin plus nivolumab therapy for unresectable advanced gastric cancer and developed clinically suspected immune-related encephalitis 2 days after surgery. All three patients required intensive care management with temporary ventilatory support. Appropriate treatment was performed, and all patients are alive and undergoing postoperative treatment.ConclusionAs immune checkpoint inhibitors are increasingly incorporated into multidisciplinary treatment for gastric cancer, surgeons may encounter severe perioperative immune-related adverse events requiring intensive care management. Awareness of these presentations and prompt multidisciplinary management may help facilitate early recognition and appropriate treatment. Background In recent years, the development of immune checkpoint inhibitors (ICIs) has significantly transformed treatment strategies for gastric cancer. Nivolumab, an anti-PD-1 antibody, has demonstrated efficacy against gastric cancer and reported high treatment efficacy [1, 2]. On the other hand, immune-related adverse events (irAEs) associated with ICIs have been widely reported and may require intensive care management in severe cases [3–5]. We present three cases of advanced gastric cancer treated with nivolumab that developed irAEs in the early period after surgery and required systemic management in the intensive care unit (ICU). Case presentation Case1 A 46-year-old Japanese female with no past medical history was referred to our hospital complaining of a feeling of food getting stuck and weight loss. Upper gastrointestinal endoscopy detected a circumferential tumor at the esophagogastric junction and intramural metastasis into the esophagus (Fig. 1a, b). The biopsy revealed moderately to poorly differentiated adenocarcinoma. Contrast-enhanced CT showed swollen lymph nodes on the lesser curvature side and ascites in the Douglas pouch and lymph nodes of #1 and #3 had multiple lesions with a longest diameter of 15 mm or more, resulting in a diagnosis of Bulky N positivity (Fig. 2a, b), leading to a diagnosis of unresectable locally advanced esophagogastric junction cancer with Siewert typeⅡ and cT4a, N2, M0, Stage III (UICC TNM 8th edition). Following tumor reduction, curative surgery was planned, and systemic chemotherapy with S-1, oxaliplatin and nivolumab (SOX + Nivo) was initiated, with a total of six courses administered. After completing six courses, the upper gastrointestinal endoscopy (Fig. 1c, d) and contrast-enhanced CT revealed tumor reduction (Fig. 2c, d), and we performed staging laparoscopy. Intraoperative findings revealed no macroscopic metastasis, and peritoneal lavage cytology was classified as Class I. We determined that radical resection was possible and performed laparoscopic proximal gastrectomy, D2 lymph node dissection, and thoracoscopic gastro-esophageal anastomosis (Ivor–Lewis’s procedure). The final pathological diagnosis was ypT4a, N1a, M0, Stage III A (UICC TNM 8th edition), CT grade 2a, Becker classification Grade 2 (Fig. 3).Fig. 1Upper gastrointestinal endoscopy images of case 1 before and after chemotherapy. a, b Images before chemotherapy. The upper gastrointestinal endoscopy detected a Siewert typeⅡ tumor around the entire circumference of the esophagogastric junction. Multiple nodular lesions suggestive of intramural metastasis were observed on the side of esophagus. c, d Images after chemotherapy. The primary tumor was observed to have shrunk. Part of the intramural metastasis disappeared, and the lesion near the primary tumor also shrunkFig. 2Contrast-enhanced CT images of case 1 before and after chemotherapy. a, b Images before chemotherapy. The contrast-enhanced CT detected a slightly unclear contrast-enhancing area and enlargement of multiple lymph nodes of lesser curvature side and junctional area. c, d Images after chemotherapy. The contrast-enhanced CT detected that the primary tumor was shrunk and unclear, and that the lymph nodes that had been swollen prior to chemotherapy had shrunkFig. 3Photographic image of resected specimen in case 1. The tumor was type 0-IIa + IIc, with scattered tumor tissue against a background of fibrosis, and findings of regression following chemotherapy. The esophageal invasion was 28 mm, and the resection margins on the oral and anal sides were negative Upper gastrointestinal endoscopy images of case 1 before and after chemotherapy. a, b Images before chemotherapy. The upper gastrointestinal endoscopy detected a Siewert typeⅡ tumor around the entire circumference of the esophagogastric junction. Multiple nodular lesions suggestive of intramural metastasis were observed on the side of esophagus. c, d Images after chemotherapy. The primary tumor was observed to have shrunk. Part of the intramural metastasis disappeared, and the lesion near the primary tumor also shrunk Contrast-enhanced CT images of case 1 before and after chemotherapy. a, b Images before chemotherapy. The contrast-enhanced CT detected a slightly unclear contrast-enhancing area and enlargement of multiple lymph nodes of lesser curvature side and junctional area. c, d Images after chemotherapy. The contrast-enhanced CT detected that the primary tumor was shrunk and unclear, and that the lymph nodes that had been swollen prior to chemotherapy had shrunk Photographic image of resected specimen in case 1. The tumor was type 0-IIa + IIc, with scattered tumor tissue against a background of fibrosis, and findings of regression following chemotherapy. The esophageal invasion was 28 mm, and the resection margins on the oral and anal sides were negative The postoperative course was uneventful, and she was discharged on the 16th postoperative day. On the 37th postoperative day, she presented severe thirst and generalized fatigue, and laboratory findings revealed a pH of 6.952, blood glucose level of 1295 mg/dL, fasting serum C-peptide level of 0.1 ng/mL, and HbA1c of 9.4%, indicating acidosis and hyperglycemia. Other endocrine function tests were no significant abnormalities, and she was diagnosed with diabetic ketoacidosis (DKA) and fulminant type 1 diabetes mellitus (FT1DM). Because of unstable breathing, she was treated in the intensive care unit with artificial respiration and intensive insulin therapy (221 days after starting SOX + Nivo therapy, 116 days after the last SOX + Nivo therapy). She was extubated on the second day of admission and transferred from the ICU to a general ward on the third day. Insulin self-injection for blood glucose management was initiated, and she was discharged home on the 10th day of admission. Postoperative adjuvant therapy with SOX plus nivolumab was administered in eight courses starting on the 100th day after the initial surgery. To date, there has been no recurrence of irAEs, and gastric cancer has not recurred and is still under observation. Case2 A 78-year-old Japanese male with a history of type 2 diabetes was referred to our hospital complaining with fatigue and dyspnea on exertion. Blood tests revealed severe anemia with Hb 5.8 g/dL. Upper gastrointestinal endoscopy detected a tumor extending from the cardia to the lesser curvature and posterior wall of the lower stomach, with suspected invasion of the esophagus (Fig. 4a, b). A biopsy revealed well-differentiated to poorly differentiated adenocarcinoma. Contrast-enhanced CT detected the para-aortic lymph nodes was swollen (#16a2lat) (Fig. 5a, b), and he was diagnosed with unresectable advanced gastric cancer, cT4a, N1, M1 (PAN), Stage IVB (UICC TNM 8th edition). As initial treatment, systemic chemotherapy with SOX + Nivo was administered for four courses, and tumor shrinkage was observed on post-treatment the upper gastrointestinal endoscopy (Fig. 4c, d) and contrast-enhanced CT scan (Fig. 5c, d). We performed a staging laparoscopy, which revealed no obvious macroscopic peritoneal dissemination, and peritoneal fluid cytology was classified as Class II. Since tumor shrinkage was maintained on imaging, we planned radical resection, including para-aortic lymph node dissection.Fig. 4Upper gastrointestinal endoscopy images of case 2 before and after chemotherapy. a, b Images before chemotherapy. The upper gastrointestinal endoscopy detected a type II advanced gastric cancer measuring 100 mm in diameter extending from the cardia to posterior wall on the lesser curvature of the upper third of stomach. The endoscopic diagnosis was T4a(SE). The ulcerative lesions with surrounding induration extend from the lesser curvature to the posterior wall. The esophageal invasion was approximately 20 mm. c, d Images after chemotherapy. The upper gastrointestinal endoscopy detected a marked shrinkage of the tumor. Esophageal invasion also decreased, and a negative biopsy was performed 25 mm from the junctional zone on the oral side, confirming the negative resultFig. 5Contrast-enhanced CT images of case 2 before and after chemotherapy. a, b Contrast-enhanced CT detected multiple swollen lymph nodes on the lesser curvature side and swollen para-aortic lymph nodes (#16a2lat). c, d Images after chemotherapy. The contrast-enhanced CT detected a marked shrinkage of the primary tumor and lymph nodes on the lesser curvature side and para-aortic lymph nodes Upper gastrointestinal endoscopy images of case 2 before and after chemotherapy. a, b Images before chemotherapy. The upper gastrointestinal endoscopy detected a type II advanced gastric cancer measuring 100 mm in diameter extending from the cardia to posterior wall on the lesser curvature of the upper third of stomach. The endoscopic diagnosis was T4a(SE). The ulcerative lesions with surrounding induration extend from the lesser curvature to the posterior wall. The esophageal invasion was approximately 20 mm. c, d Images after chemotherapy. The upper gastrointestinal endoscopy detected a marked shrinkage of the tumor. Esophageal invasion also decreased, and a negative biopsy was performed 25 mm from the junctional zone on the oral side, confirming the negative result Contrast-enhanced CT images of case 2 before and after chemotherapy. a, b Contrast-enhanced CT detected multiple swollen lymph nodes on the lesser curvature side and swollen para-aortic lymph nodes (#16a2lat). c, d Images after chemotherapy. The contrast-enhanced CT detected a marked shrinkage of the primary tumor and lymph nodes on the lesser curvature side and para-aortic lymph nodes On the day after we performed the staging laparoscopy (97 days after starting Sox + Nivo therapy and 36 days after the last Sox + Nivo therapy), he developed itching all over the body, but the symptoms were relatively mild and were treated with symptomatic treatment using antihistamines. He was discharged on the second postoperative day, and symptomatic treatment was continued after discharge. However, on postoperative day 13 (109 days after starting Sox + Nivo therapy and 48 days after the last SOX + Nivo therapy), a polymorphic exudative erythema-like rash was observed (Fig. 6a, b), and topical and oral corticosteroids were started. On the 16th postoperative day, he visited our hospital complaining severe dyspnea and fatigue. There was minimal improvement in the rash, but with pH: 6.901, blood glucose: 745 mg/dL, serum C-peptide: 0.3 ng/mL, and HbA1c: 7.4%, leading to DKA. This was determined to be an irAE associated with ICI therapy. Emergency admission was initiated on the same day (113 days after initiation of SOX + Nivo therapy and 52 days after the last dose of SOX + Nivo therapy). Due to unstable breathing and to resolve respiratory failure, we treated him on mechanical ventilation in the ICU. He was extubated on the day after admission, and subsequent examination revealed a diagnosis of FT1DM, and intensive insulin therapy was initiated. On the fourth day of admission, he was transferred from the ICU to a general ward. On the eighth day of hospitalization, widespread bullous lesions were observed all over the body (Fig. 7a, b), and skin biopsy confirmed a diagnosis of bullous pemphigoid (BP) (124 days after initiation of SOX + Nivo therapy and 63 days after the last dose of SOX + Nivo therapy). Due to the rapid progression of skin symptoms, steroid pulse therapy, intravenous immunoglobulin therapy, and plasma exchange therapy were sequentially administered. His general condition gradually improved, and he was discharged from the hospital on the 77th day of admission. We performed CT scan 170 days after the staging laparoscopy and found that the primary tumor and para-aortic lymph nodes remained shrunk. We decided to perform radical surgery. We performed laparoscopic total gastrectomy and D2 lymph node dissection 204 days after diagnostic laparoscopy. Considering the history of BP, we did not perform para-aortic lymph node dissection to avoid excessive invasion. The postoperative course was uneventful, and he was discharged from the hospital on the 10th postoperative day. The pathological diagnosis was ypT0, N0, M0, Stage 0 (UICC TNM 8th edition), CT Grade 3, Becker classification Grade 1a (Fig. 8). Since then, the patient has been receiving S-1 monotherapy as adjuvant therapy for 1 year while gradually reducing the dose of corticosteroids. At 1 year and 6 months after surgery, there has been no recurrence of irAEs, and the gastric cancer has not recurred and is still under observation.Fig. 6Polymorphic exudative erythema-like rash was observed throughout the body on the 13th day after surgeryFig. 7Patient presented with generalized vesicular lesions, which ruptured and formed crusts. Similar symptoms spread not only to the trunk but also to the limbs and extremitiesFig. 8Photographic image of resected specimen in case 2. The resected specimen was pathologically complete response, with extensive fibrosis but no residual tumor tissue. The margins on the oral and anal sides were negative Polymorphic exudative erythema-like rash was observed throughout the body on the 13th day after surgery Patient presented with generalized vesicular lesions, which ruptured and formed crusts. Similar symptoms spread not only to the trunk but also to the limbs and extremities Photographic image of resected specimen in case 2. The resected specimen was pathologically complete response, with extensive fibrosis but no residual tumor tissue. The margins on the oral and anal sides were negative Case3 A 64-year-old Japanese male with no previous medical history was referred to our hospital complaining of upper abdominal pain and dyspnea on exertion. He was found to have severe anemia with Hb of 6.9 g/dL. The upper gastrointestinal endoscopy detected a sub-circumferential tumor in the middle posterior wall of the stomach, and biopsy revealed poorly to well-differentiated adenocarcinoma (Fig. 9a). Contrast-enhanced CT detected swollen lymph nodes on the lesser curvature side and para-aortic lymph nodes (#16b1lat, #16b1pre) (Fig. 10a, b), leading to a diagnosis of unresectable advanced gastric cancer, cT4a, N2, M1 (PAN), Stage IVB (UICC TNM 8th edition). Three courses of SOX + Nivo were performed as initial treatment, and tumor shrinkage was confirmed by the upper gastrointestinal endoscopy (Fig. 9b) and contrast-enhanced CT scan (Fig. 10c, d). We performed distal gastrectomy with D2 lymph node dissection and para-aortic lymph node sampling with curative intent. Intraoperative peritoneal lavage cytology was negative (CY0). Given the favorable response to preoperative chemotherapy and the presence of only a single peritoneal nodule, we considered that complete macroscopic resection might still be achievable and, therefore, proceeded with resection. During surgery, a single white nodule was identified on the transverse mesocolon, resected, and submitted for frozen-section analysis, which revealed adenocarcinoma, leading to a diagnosis of peritoneal dissemination (pP1a). Because the para-aortic #16b1 lymph nodes had been considered metastatic on preoperative imaging, they were sampled to assess treatment response. These nodes were not submitted for frozen-section analysis, but permanent histopathological examination later confirmed metastatic involvement. The final pathological diagnosis was ypT4a, N3b, M1 (PER), P1a, CY0, Stage IV (UICC TNM 8th edition), CT Grade 2a, and Becker classification Grade 2 (Fig. 11). On the second postoperative day, he suddenly developed impaired consciousness, urinary incontinence, and multiple generalized seizures (86 days after initiation of SOX + nivolumab therapy and 44 days after the last dose). He was diagnosed with status epilepticus and transferred to the intensive care unit, where he was managed with deep sedation and mechanical ventilation. The following day, sedation was discontinued, and he was successfully extubated without further seizures. However, on postoperative day 12, he developed psychiatric symptoms, including delusions of persecution, guilt, and poverty. Brain MRI revealed no structural abnormalities. Based on the temporal association with immune checkpoint inhibitor therapy, the occurrence of seizures followed by psychiatric symptoms, and the exclusion of major alternative causes, such as infection and other organic diseases, we clinically suspected immune-related encephalitis and initiated steroid pulse therapy. After that, his psychiatric symptoms gradually improved following treatment, and they had completely resolved by postoperative day 21, after which he was discharged. Although a detailed neurologic workup, including electroencephalography and cerebrospinal fluid analysis, had been performed at another institution, these results were not available for review at our hospital. Therefore, the diagnosis should be interpreted as clinically suspected rather than definitively confirmed. After discharge, we gradually tapered corticosteroids and initiated postoperative adjuvant therapy with S-1 monotherapy on postoperative day 129. However, contrast-enhanced CT at 6 months postoperatively revealed adrenal and bone metastases, so treatment was switched to SOX therapy without Nivolumab. Furthermore, imaging studies at 1-year post-surgery revealed progression of adrenal, para-aortic lymph node, and bone metastases, leading to a switch to paclitaxel and ramucirumab therapy, which is still ongoing.Fig. 9Upper gastrointestinal endoscopy images of case 3 before and after chemotherapy. a Image before chemotherapy. The upper gastrointestinal endoscopy detected a type III advanced gastric cancer extending sub-circumferentially from the lower third of stomach to the posterior wall on the lesser curvature side of the antrum. b Image after chemotherapy. The upper gastrointestinal endoscopy detected that the primary tumor had slightly shrunk. However, the ulcerative lesion remainedFig. 10Contrast-enhanced CT images of case 3 before and after chemotherapy. a, b Images before chemotherapy. The contrast-enhanced CT detected lymph nodes in the lesser curvature and para-aortic area (#16b1lat, #16b1pre). c, d Images after chemotherapy. The contrast-enhanced CT detected swollen lymph nodes on the lesser curvature side and para-aortic lymph nodes (#16b1lat, #16b1pre)Fig. 11Photographic image of resected specimen in case 3. The resected specimen revealed residual tumor tissue against a background of fibrosis. Part of the tumor was exposed to the serosa. The oral and anal margins were negative Upper gastrointestinal endoscopy images of case 3 before and after chemotherapy. a Image before chemotherapy. The upper gastrointestinal endoscopy detected a type III advanced gastric cancer extending sub-circumferentially from the lower third of stomach to the posterior wall on the lesser curvature side of the antrum. b Image after chemotherapy. The upper gastrointestinal endoscopy detected that the primary tumor had slightly shrunk. However, the ulcerative lesion remained Contrast-enhanced CT images of case 3 before and after chemotherapy. a, b Images before chemotherapy. The contrast-enhanced CT detected lymph nodes in the lesser curvature and para-aortic area (#16b1lat, #16b1pre). c, d Images after chemotherapy. The contrast-enhanced CT detected swollen lymph nodes on the lesser curvature side and para-aortic lymph nodes (#16b1lat, #16b1pre) Photographic image of resected specimen in case 3. The resected specimen revealed residual tumor tissue against a background of fibrosis. Part of the tumor was exposed to the serosa. The oral and anal margins were negative Discussion In recent years, the development of ICIs has significantly transformed treatment strategies for gastric cancer. Nivolumab has demonstrated efficacy in the CheckMate-649 trial and the ATTRACTION-4 trial, establishing it as a treatment option for gastric cancer [1, 2]. On the other hand, there are a variety of symptoms of irAEs, including skin disorders, endocrine disorders, and neurotoxicity, affecting multiple organs, and the symptoms can range from mild to severe, occasionally requiring intensive care management [3–5]. While most previous reports of ICU admission due to irAEs have involved cases during chemotherapy or maintenance therapy, we reported three cases of severe irAEs with acute onset during the perioperative period requiring intensive care. In case 1, there was no history of diabetes before surgery, and preoperative HbA1c was within the normal range (6.0% on 12 days before surgery). Despite regular blood glucose monitoring during preoperative treatment, she developed a rapid course. Patho-physiologically, it is proposed that ICI induces an autoimmune response that directly attacks pancreatic β-cells, and that direct stress on the pancreas further exacerbates the autoimmune response, leading to onset [6]. In gastric cancer surgery, we suspect that the technique of lymph node dissection at the upper edge of the pancreas may cause local inflammatory stress to the pancreas, increasing the risk of onset. Therefore, careful follow-up is necessary during the period after the start of ICI treatment, especially if it overlaps with the perioperative period, and the possibility of delayed onset after discontinuation of ICI should also be considered [7]. In case 2, BP tends to develop later than typical skin manifestations of irAE. Pathologically, BP involves B-cell-mediated auto-antibody production and exhibits significant autoimmune disease characteristics [8–10]. Therefore, BP may persist or worsen even after discontinuation of ICIs [8–10]. In this case, the inflammatory cytokines and stress hormones produced due to surgical intervention may have activated the immune system, increasing the opportunity for self-antigens at the epidermal–dermal junction to be exposed through direct physical stimulation of the skin by surgical procedures or dressing materials, as well as the wound healing process, and the modification of the autoimmune mechanism by ICI may have contributed to triggering the onset of BP. This case developed approximately 14 weeks after the initiation of nivolumab, which is slightly earlier than previously reported [8–10]. Therefore, surgical intervention may have contributed to the early onset of BP. As reported previously, skin symptoms progressed in stages, from pruritus to polymorphic exudative erythema-like rash. Although it is difficult to suspect BP as irAE earlier, if ICI treatment is performed perioperatively, we should consider such mechanisms and conduct careful perioperative follow-up. The incidence rate of neurological irAEs is approximately 1.5%, with severe cases reported as 0.2–0.8%. The time from initiation of ICI therapy to onset ranges from within 24 h to over 1 year, as reported [11–13]. In Case 3, postoperative neurologic symptoms raised concern for a neurologic irAE. The diagnosis of immune-related encephalitis was made on a clinical basis, considering the temporal association with nivolumab exposure, the occurrence of seizures followed by psychiatric symptoms, the absence of structural abnormalities on brain MRI, and the exclusion of major alternative causes, such as infection and other organic diseases [11–13]. However, because detailed neurologic investigations, including electroencephalography and cerebrospinal fluid analysis, were performed at another institution and were not available for review at our hospital, this diagnosis should be interpreted as clinically suspected rather than definitively confirmed. Previous reports have shown that recurrence can occur during steroid tapering or after ICI re-administration. Therefore, in patients with suspected neurologic irAEs, subsequent treatment decisions should be made cautiously, taking into account both oncologic benefit and the potential risk of recurrent toxicity. Even when neurologic test findings are non-specific or incomplete, immune-related encephalitis should remain in the differential diagnosis in patients who develop new central nervous system symptoms after ICI exposure [11, 13]. In addition, 64% of cases with encephalitis also concurrently developed other irAEs (such as dermatitis, hepatitis, or thyroiditis) [11], so it is important to screen other irAEs at the time of encephalitis onset. This case coexisted with T1DM and like case 2, multiple irAEs were present. Given the diagnostic uncertainty and the potential risk of recurrent neurologic toxicity, postoperative treatment decisions in Case 3 were made cautiously after multidisciplinary discussion. Re-administration of ICI was avoided, taking into account both the suspected neurologic irAE and the patient’s overall oncologic condition. In this report, all patients developed worsening respiratory condition and required intensive care management with intubation. A high proportion (26%) of patients required ICU management due to irAEs [12], but there were no reports on perioperative cases, and it is often difficult to distinguish between postoperative complications and irAEs, especially in cases of postoperative onset. In this report, the irAEs onsets occurred on different durations (case 1 was 221 days, case 2 was 124 days, and case 3 was 86 days after initiation), which differs from the previously reported onset periods [13]. In addition, these onsets were in the early postoperative period (case 1 was 37 days, case 2 was 13 days and case 3 was 2 days after surgery). In our three cases, severe irAEs developed at different intervals after ICI initiation and in the early postoperative period. Although causality cannot be established from this small case series, perioperative inflammatory and physiologic stress may have influenced the timing and severity of irAE onset. Previous reports have shown that preoperative ICI treatment can shrink tumors and lead to complete resection, and that appropriate treatment of irAEs can further improve prognosis [14–16]. In recent years, with the incorporation of ICI into perioperative therapy, it is anticipated that the opportunity for us to perform surgery in cases, where high therapeutic efficacy is achieved, such as conversion surgery, will increase. Although reports on the safety of ICI during the perioperative period are limited, some studies have reported no increase in CTCAE Grade 3–4 adverse events when appropriate patient selection was made [17]. On the other hand, there have been reports that severe irAE makes it difficult to continue ICI treatment and leads to poor prognosis [18]. In this report, all cases presented with severe irAEs following surgical treatment, with varying degrees of surgical invasiveness and the types, onset, and duration of irAEs also differing among cases. In this report, all cases presented with severe irAEs following surgery, although the degree of surgical invasiveness, timing of onset, and type of irAE varied. Given the diversity of irAEs, careful assessment of the risk of recurrence or new irAEs is warranted before resuming ICI therapy. Multidisciplinary management, including collaboration with medical oncologists, is essential. Conclusion We reported three cases of irAEs that developed during the perioperative period and required intensive care management. ICI therapy for gastric cancer is continuing to advance, and an increase in perioperative ICI onset is expected in the future. Surgeons managing perioperative care need to acquire knowledge of irAE and its treatment methods. We hope that this report will contribute to preventing the severe progression of irAEs and helping patients continue their treatment.